|
Positive ferric chloride test
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
RESULTS FTCD is significantly downregulated in HCC tissues and cell lines.
|
31203308 |
2019 |
|
Autoimmune Chronic Hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
We investigated the role of HLA-DR4 in the development of AIH by immunization of HLA-DR4 (DR4) transgenic non-obese diabetic (NOD) mice with DNA coding for human CYP2D6/FTCD fusion autoantigen.
|
27414259 |
2016 |
|
Autoimmune hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
We investigated the role of HLA-DR4 in the development of AIH by immunization of HLA-DR4 (DR4) transgenic non-obese diabetic (NOD) mice with DNA coding for human CYP2D6/FTCD fusion autoantigen.
|
27414259 |
2016 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings suggested crosstalk between FTCD and HIF signaling and promoted HCC progression, thus implicating FTCD as a therapeutic target for HCC.
|
24686083 |
2014 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The sensitivity and specificity of individual markers or a combination for the detection of HCC were 51.8% and 95.6% for CHC, 61.4% and 98.5% for FTCD, and 80.7% and 94.1% for CHC+FTCD, respectively.
|
18571811 |
2008 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Two gene products, glyceraldehyde-3-phosphate dehydrogenase and formimidoyltransferase-cyclodeaminase, were identified from inversely altered spots, suggesting that different isoforms or post-translational modifications of these two proteins might play different roles in HCC.
|
17627933 |
2007 |
|
Autoimmune Chronic Hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The current study shows that a murine model of AIH can be generated by DNA immunization against type 2 AIH self-antigens (P450 2D6 and formiminotransferase-cyclodeaminase).
|
15057911 |
2004 |
|
Autoimmune hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The current study shows that a murine model of AIH can be generated by DNA immunization against type 2 AIH self-antigens (P450 2D6 and formiminotransferase-cyclodeaminase).
|
15057911 |
2004 |
|
Autoimmune Chronic Hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to identify the dominant epitope on human FTCD and to analyze antigenic-site sequences for clues on the development of AIH.
|
12811847 |
2003 |
|
Autoimmune hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to identify the dominant epitope on human FTCD and to analyze antigenic-site sequences for clues on the development of AIH.
|
12811847 |
2003 |
|
Autoimmune Chronic Hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis.
|
10029623 |
1999 |
|
Autoimmune hepatitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis.
|
10029623 |
1999 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Low FTCD expression is correlated with a poor prognosis (P<0.001) and an aggressive tumor phenotype, including AFP levels (P=0.009), tumor size (P=0.013), vascular invasion (P=0.001), BCLC stage (P=0.024), and pTNM stage (P<0.001).
|
31203308 |
2019 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Interestingly, CHC and FTCD expression was strikingly different between tumor and nontumor tissues.
|
18571811 |
2008 |
|
Inherited disorder of folate metabolism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Glutamate formiminotransferase deficiency (FTCD deficiency) or formiminoglutamic aciduria is the second most common of the known inherited disorders of folate metabolism.
|
30740726 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Low FTCD expression is correlated with a poor prognosis (P<0.001) and an aggressive tumor phenotype, including AFP levels (P=0.009), tumor size (P=0.013), vascular invasion (P=0.001), BCLC stage (P=0.024), and pTNM stage (P<0.001).
|
31203308 |
2019 |
|
Blood spots
|
0.010 |
Biomarker
|
disease |
BEFREE |
In many states, FTCD deficiency can be incidentally detected on tandem mass spectrometry-based newborn screening of dried blood spots.
|
30740726 |
2019 |
|
Nicotine Dependence
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to test whether individual differences in the level of nicotine dependence (as measured by the Fagerstrom Test of Cigarette Dependence [FTCD]) and/or the rate of nicotine metabolism influence smoking behavior and exposure to tobacco toxicants when smokers are switched to reduced nicotine content cigarettes (RNC).
|
25555385 |
2015 |
|
Adenoviral infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We developed a new model of experimental murine AIH (emAIH) by a self-limited adenoviral infection with the hepatic autoantigen formiminotransferase cyclodeaminase (FTCD).
|
23475565 |
2013 |
|
Nodule
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, CHC and FTCD were useful to distinguish early HCC from benign tumors such as regenerative nodule or focal nodular hyperplasia, because the sensitivity and specificity of the markers are 41.2% and 77.8% for CHC, 44.4% and 80.0% for FTCD, which is comparable with those of glypican-3 (33.3% and 100%).
|
18571811 |
2008 |
|
Focal Nodular Hyperplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Moreover, CHC and FTCD were useful to distinguish early HCC from benign tumors such as regenerative nodule or focal nodular hyperplasia, because the sensitivity and specificity of the markers are 41.2% and 77.8% for CHC, 44.4% and 80.0% for FTCD, which is comparable with those of glypican-3 (33.3% and 100%).
|
18571811 |
2008 |